全文获取类型
收费全文 | 171篇 |
免费 | 12篇 |
专业分类
各国政治 | 6篇 |
工人农民 | 2篇 |
世界政治 | 3篇 |
外交国际关系 | 15篇 |
法律 | 83篇 |
中国共产党 | 14篇 |
中国政治 | 3篇 |
政治理论 | 6篇 |
综合类 | 51篇 |
出版年
2021年 | 1篇 |
2020年 | 6篇 |
2019年 | 5篇 |
2018年 | 1篇 |
2017年 | 8篇 |
2016年 | 3篇 |
2015年 | 3篇 |
2014年 | 3篇 |
2013年 | 8篇 |
2012年 | 15篇 |
2011年 | 9篇 |
2010年 | 9篇 |
2009年 | 17篇 |
2008年 | 13篇 |
2007年 | 12篇 |
2006年 | 20篇 |
2005年 | 8篇 |
2004年 | 10篇 |
2003年 | 8篇 |
2002年 | 8篇 |
2001年 | 2篇 |
2000年 | 3篇 |
1999年 | 2篇 |
1998年 | 1篇 |
1997年 | 2篇 |
1996年 | 2篇 |
1992年 | 1篇 |
1988年 | 1篇 |
1986年 | 1篇 |
1984年 | 1篇 |
排序方式: 共有183条查询结果,搜索用时 0 毫秒
181.
Suely K. S. S. Porto M.S. Thiago Nogueira Ph.D. Lucas Blanes Ph.D. Philip Doble Ph.D. Bruno D. Sabino Ph.D. Claudimir L. do Lago Ph.D. Lúcio Angnes Ph.D. 《Journal of forensic sciences》2014,59(6):1622-1626
A method for the identification of 3,4‐methylenedioxymethamphetamine (MDMA) and meta‐chlorophenylpiperazine (mCPP) was developed employing capillary electrophoresis (CE) with capacitively coupled contactless conductivity detection (C4D). Sample extraction, separation, and detection of “Ecstasy” tablets were performed in <10 min without sample derivatization. The separation electrolyte was 20 mm TAPS/Lithium, pH 8.7. Average minimal detectable amounts for MDMA and mCPP were 0.04 mg/tablet, several orders of magnitude lower than the minimum amount encountered in a tablet. Seven different Ecstasy tablets seized in Rio de Janeiro, Brazil, were analyzed by CE‐C4D and compared against routine gas chromatography‐mass spectrometry (GC‐MS). The CE method demonstrated sufficient selectivity to discriminate the two target drugs, MDMA and mCPP, from the other drugs present in seizures, namely amphepramone, fenproporex, caffeine, lidocaine, and cocaine. Separation was performed in <90 sec. The advantages of using C4D instead of traditional CE‐UV methods for in‐field analysis are also discussed. 相似文献
182.
Settlement and trial expenditures are crucially interrelated. The literature on settlement, however, takes no account of models of trial. In this paper, we develop a unified model of settlement and trial expenditures. We do this by discarding the usual assumption of settlement models that trial costs are constant across cases. Instead, we follow the literature on trial by permitting trial costs to vary with the legal merit of the plaintiff's case. Our approach can be used to extend standard models of settlement such as the well-known Priest–Klein model as well as models based on asymmetric information. As a demonstration, we extend the Priest–Klein model and generally overturn that model's canonical results. In particular, we show that even in a fully symmetric model, predicted win rates at trial can deviate substantially from 50 percent. Furthermore, win rates will vary in response to legal reforms that shift the decision standard. 相似文献
183.
目的 观察Ⅲ~Ⅳ期糖尿病肾病(diabetic nephropathy,DN)气阴两虚、瘀血阻络证患者血清胱抑素C(cystatin C,CysC)、尿纤维连接蛋白(urinary fibronectin,UFn)水平及糖肾康颗粒的干预作用。方法 将60例Ⅲ~Ⅳ期糖尿病肾病气阴两虚、瘀血阻络证患者随机分为治疗组和对照组,各30例,并选取20名健康体检者作为正常组。治疗组与对照组均给予常规降糖、降压治疗,治疗组加用糖肾康颗粒,疗程2个月。治疗前后分别检测治疗组与对照组尿白蛋白/尿肌酐比值(microalbuminuria/urine creatinine,MAU/UCr)、肾小球滤过率估算值(estimated glomerular filtration rate,eGFR)以及CysC、UFn水平,并与正常组比较。结果 治疗组中医证候疗效显著优于对照组(P<0.01);在降低MAU/UCr比值和CysC、UFn水平,以及升高eGFR水平方面,治疗组显著优于对照组(P<0.01)。结论 糖肾康颗粒可降低Ⅲ~Ⅳ期DN气阴两虚、瘀血阻络证患者血清CysC、UFn水平,并可减少DN患者尿蛋白排泄,维持肾小球滤过率,在一定程度上具有保护肾功能、延缓疾病进展的作用。 相似文献